Solid Lipid Nanoparticles Bearing Flurbiprofen for Transdermal Delivery

Figures & data

TABLE 1 Optimization of stearic acid/cholesterol ratio with regard to average particle size

	Ratio of	Average
Formulation	stearic acid:	particle	Polydispersity
code	cholesterol (w/w)	size (nm)	index
SLN-I	9:1	990	0.894
SLN-II	8:2	920	0.813
SLN-III	6:4	890	0.939
SLN-IV	5:5	880	0.652
SLN-V	4:6	720	0.417
SLN-VI	2:8	700	0.448
SLN-VII*	1:9	640	0.379

TABLE 2 Optimization of soya lecithin/lipid ratio to maximize solid lipid nanoparticles/liposomes ratio

		Quantity of
	Ratio of soya	carboxyfluorescein
Formulation	lecithin/lipid	recovered
code	(w/w)	(%)
SLN-VII A	0.2/1	89.35
SLN-VII B	0.4/1	88.71
SLN-VII C*	0.5/1	86.92
SLN-VII D	0.6/1	78.35
SLN-VII E	0.8/1	69.37
SLN-VII F	1/1	62.93

FIG. 1 Effect of pluronic F-68/lipid w/w ratio on average particle size and percent drug entrapment in SLN dispersions.

FIG. 2 Effect of sonication time on average particle size and percent drug entrapment in SLN dispersions.

FIG. 3 Scanning electron photomicrograph of SLN.

TABLE 3 Zeta potential of solid lipid nanoparticles dispersions

Formulation	Zeta	Percent drug
code	potential (mV)	entrapment
SLN-T1	−20.2	71.50 ± 0.75
SLN-T2	−18.6	89.21 ± 0.42
SLN-T3	−17.1	78.89 ± 0.64
SLN-T4*	−49.4	92.70 ± 0.28
SLN-T1-Gel	—	67.70 ± 0.80
SLN-T2-Gel	—	83.70 ± 0.32
SLN-T3-Gel	—	72.22 ± 0.55
SLN-T4-Gel*	—	89.98 ± 0.74

FIG. 4 In vitro drug release profile of SLN dispersions in PBS (pH 4.5).

FIG. 5 In vitro drug release profile of SLN-gel formulations in PBS (pH 4.5).

TABLE 4 Rate constants of in vitro drug release and in vitro drug skin permeation of various formulations

Formulation	Release rate constant	Skin permeation rate
code	(Percent/cm^2/hr^0.8)	constant (Percent/cm^2/hr)
SLN-T1	6.8647	8.4188
SLN-T2	6.3282	7.3612
SLN-T3	6.4527	7.8233
SLN-T4	5.2526	5.207
SLN-T1-Gel	8.5797	8.7815
SLN-T2-Gel	7.9098	7.9843
SLN-T3-Gel	8.1112	8.3893
SLN-T4-Gel	6.9102	5.2243

FIG. 6 In vitro drug skin permeation profile of SLN dispersion in PBS (pH 7.4).

FIG. 7 In vitro drug skin permeation profile of SLN-gel formulations in PBS (pH 7.4).

FIG. 8 Anti-inflammatory activity of different formulations in carrageenan-induced rat paw edema.